Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Pfizer is likely to show GSK significant competition
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Construction will begin this year with the new capacity anticipated by 2025
Subscribe To Our Newsletter & Stay Updated
